S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:XGN

Exagen Stock Forecast, Price & News

$9.69
+0.72 (+8.03%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.00
$9.95
50-Day Range
$8.97
$14.44
52-Week Range
$8.75
$24.67
Volume
117,317 shs
Average Volume
60,080 shs
Market Capitalization
$156.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.46
30 days | 90 days | 365 days | Advanced Chart
Receive XGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.


Exagen logo

About Exagen

Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Headlines

Short Interest in Exagen Inc. (NASDAQ:XGN) Drops By 77.7%
November 28, 2021 |  americanbankingnews.com
Short Interest in Exagen Inc. (NASDAQ:XGN) Decreases By 77.7%
November 28, 2021 |  americanbankingnews.com
-$0.50 EPS Expected for Exagen Inc. (NASDAQ:XGN) This Quarter
November 21, 2021 |  americanbankingnews.com
Exagen Inc. (XGN) Q3 2021 Earnings Call Transcript
November 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XGN
Fax
N/A
Employees
182
Year Founded
N/A

Sales & Book Value

Annual Sales
$41.97 million
Book Value
$5.62 per share

Profitability

Net Income
$-16.69 million
Pretax Margin
-48.08%

Debt

Price-To-Earnings

Miscellaneous

Free Float
8,260,000
Market Cap
$156.63 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/15/2022

MarketRank

Overall MarketRank

2.31 out of 5 stars

Medical Sector

286th out of 1,394 stocks

Medical Laboratories Industry

7th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Exagen (NASDAQ:XGN) Frequently Asked Questions

Is Exagen a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exagen stock.
View analyst ratings for Exagen
or view top-rated stocks.

How has Exagen's stock price been impacted by COVID-19?

Exagen's stock was trading at $19.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, XGN shares have decreased by 50.5% and is now trading at $9.69.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Exagen?

Exagen saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 87,200 shares, a decline of 77.7% from the October 31st total of 390,900 shares. Based on an average daily volume of 44,900 shares, the days-to-cover ratio is presently 1.9 days. Currently, 0.9% of the company's stock are short sold.
View Exagen's Short Interest
.

When is Exagen's next earnings date?

Exagen is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Exagen
.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.42) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.04. The business had revenue of $12.25 million for the quarter, compared to the consensus estimate of $12.13 million. Exagen had a negative net margin of 48.16% and a negative trailing twelve-month return on equity of 28.14%. During the same period last year, the business earned ($0.34) EPS.
View Exagen's earnings history
.

What guidance has Exagen issued on next quarter's earnings?

Exagen issued an update on its FY 2021 earnings guidance on Wednesday, December, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $47 million-$49 million, compared to the consensus revenue estimate of $47.97 million.

What price target have analysts set for XGN?

5 analysts have issued 12-month price objectives for Exagen's shares. Their forecasts range from $20.00 to $30.00. On average, they expect Exagen's share price to reach $25.25 in the next year. This suggests a possible upside of 160.6% from the stock's current price.
View analysts' price targets for Exagen
or view top-rated stocks among Wall Street analysts.

Who are Exagen's key executives?

Exagen's management team includes the following people:
  • Mr. Fortunato Rocca, CEO, Pres & Director (Age 60, Pay $1.08M)
  • Mr. Kamal Adawi, CFO & Corp. Sec. (Age 42, Pay $620.3k)
  • Dr. Debra Jeske Zack, Chief Medical Officer (Age 64, Pay $576.66k)
  • Mr. Mark Hazeltine, Chief Operating Officer (Age 47)
  • Dr. Anja Kammesheidt Ph.D., Chief Scientific Officer
  • Mr. John Wegener, Sr. VP of Sales and Marketing (Age 52)

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen CEO Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among Exagen's employees.

When did Exagen IPO?

(XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

What is Exagen's stock symbol?

Exagen trades on the NASDAQ under the ticker symbol "XGN."

Who are Exagen's major shareholders?

Exagen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Cowen AND Company LLC (8.59%), Wasatch Advisors Inc. (6.81%), BlackRock Inc. (3.62%), Morgan Stanley (3.09%), Stonepine Capital Management LLC (2.42%) and Deutsche Bank AG (1.36%). Company insiders that own Exagen stock include Hunt Holdings Limited Partners, James L L Tullis, Nmsic Co-Investment Fund, LP and Wendy S Johnson.
View institutional ownership trends for Exagen
.

Which major investors are selling Exagen stock?

XGN stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Deutsche Bank AG, Millennium Management LLC, Calamos Advisors LLC, California State Teachers Retirement System, New York State Common Retirement Fund, Russell Investments Group Ltd., and BlackRock Inc.. Company insiders that have sold Exagen company stock in the last year include Hunt Holdings Limited Partners, James L L Tullis, and Nmsic Co-Investment Fund, LP.
View insider buying and selling activity for Exagen
or view top insider-selling stocks.

Which major investors are buying Exagen stock?

XGN stock was purchased by a variety of institutional investors in the last quarter, including Cowen AND Company LLC, Stonepine Capital Management LLC, Cowen Prime Advisors LLC, Morgan Stanley, Natixis, Penbrook Management LLC, Geode Capital Management LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Exagen
or or view top insider-buying stocks.

How do I buy shares of Exagen?

Shares of XGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exagen's stock price today?

One share of XGN stock can currently be purchased for approximately $9.69.

How much money does Exagen make?

Exagen has a market capitalization of $156.63 million and generates $41.97 million in revenue each year. The company earns $-16.69 million in net income (profit) each year or ($1.55) on an earnings per share basis.

How many employees does Exagen have?

Exagen employs 182 workers across the globe.

What is Exagen's official website?

The official website for Exagen is www.exagen.com.

Where are Exagen's headquarters?

Exagen is headquartered at 1261 Liberty Way Suite C, VISTA CA, 92081.

How can I contact Exagen?

Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The company can be reached via phone at 760-560-1501 or via email at [email protected].


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.